Valuation Update With 7 Day Price Move • Jul 28
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to CN¥7.95, the stock trades at a trailing P/E ratio of 23.7x. Average trailing P/E is 41x in the Chemicals industry in China. Total loss to shareholders of 63% over the past three years. Anuncio • Jun 30
Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026 Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026 Anuncio • May 25
Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 15, 2026 Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 15, 2026, at 14:00 China Standard Time. Location: No. 89, Hi-tech Park 3rd Road, Donghu New Technology Development Zone, Wuhan, Hubei China New Risk • May 12
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 95% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (13% net profit margin). Reported Earnings • Apr 24
First quarter 2026 earnings released: CN¥0.26 loss per share (vs CN¥0.27 profit in 1Q 2025) First quarter 2026 results: CN¥0.26 loss per share (down from CN¥0.27 profit in 1Q 2025). Revenue: CN¥11.0m (down 93% from 1Q 2025). Net loss: CN¥43.6m (down 197% from profit in 1Q 2025). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. New Risk • Apr 24
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 13% Last year net profit margin: 24% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (13% net profit margin). Valuation Update With 7 Day Price Move • Apr 23
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥16.02, the stock trades at a trailing P/E ratio of 17.1x. Average trailing P/E is 48x in the Chemicals industry in China. Total loss to shareholders of 38% over the past three years. Anuncio • Mar 30
Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026 Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026 Reported Earnings • Mar 05
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.94 (up from CN¥0.74 in FY 2024). Revenue: CN¥574.9m (up 3.5% from FY 2024). Net income: CN¥156.7m (up 26% from FY 2024). Profit margin: 27% (up from 22% in FY 2024). The increase in margin was primarily driven by higher revenue. Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥20.19, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 27x in the Chemicals industry in China. Total loss to shareholders of 44% over the past three years. Anuncio • Dec 26
Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026 Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026 Anuncio • Dec 03
CABIO Showcases Life-Stage Nutrition Innovation at Fi Europe 2025 Paris At the 30th milestone edition of Food Ingredients Europe 2025, CABIO showcases its comprehensive nutritional ingredients portfolio while simultaneously announcing the official opening of its new Global Headquarter-Wuhan Synthetic Biology Innovation Hub, marking a pivotal leap forward in pioneering the future of synthetic biology. The hub embodies three core values: Deepening Innovation through an open platform uniting brilliant minds to explore synthetic biology's boundless potential; Strengthening Collaboration via dynamic spaces engineered to spark creativity and cross-disciplinary partnerships; and Amplifying Impact with advanced facilities and enhanced R&D capabilities to deliver greater value to global partners and drive sustainable industry growth. Five Core Product Lines: CABIO®?ARA delivers 20+ years of infant nutrition excellence. CABIO®?Omega-3 series, from sustainable microalgae, addresses needs from infant brain development to adult cardiovascular health. Keyshine®?HMOs 2'-FL utilizes advanced fermentation for breast milk-mimicking infant nutrition extending to adult wellness. Keyshine®?N-Acetylneuraminic Acid offers dual benefits for neurological development and skin health. Additionally, diversified application solutions provide customized partnerships across infant-to- adult nutrition spectrum. The new headquarter empowers CABIO's global expansion. With advanced R&D facilities and an open innovation platform, CABIO continues delivering premium, traceable nutritional ingredients to European and global partners, jointly driving sustainable development in nutrition and health industries. Visit CABIO's booth to explore unlimited possibilities in nutritional innovation. Reported Earnings • Oct 28
Third quarter 2025 earnings released: EPS: CN¥0.13 (vs CN¥0.098 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.13 (up from CN¥0.098 in 3Q 2024). Revenue: CN¥121.3m (down 4.0% from 3Q 2024). Net income: CN¥21.4m (up 34% from 3Q 2024). Profit margin: 18% (up from 13% in 3Q 2024). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Anuncio • Sep 30
Cabio Biotech (Wuhan) Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025 Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025 Reported Earnings • Aug 20
Second quarter 2025 earnings released: EPS: CN¥0.37 (vs CN¥0.26 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.37 (up from CN¥0.26 in 2Q 2024). Revenue: CN¥150.8m (up 4.8% from 2Q 2024). Net income: CN¥63.0m (up 45% from 2Q 2024). Profit margin: 42% (up from 30% in 2Q 2024). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Anuncio • Jun 30
Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2025 Results on Aug 19, 2025 Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2025 results on Aug 19, 2025 Anuncio • May 08
Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, May 29, 2025 Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time. Location: Meeting Room of the Company's Gedian Branch, Ezhou, Hubei China Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥19.77, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 21x in the Chemicals industry in China. Total loss to shareholders of 13% over the past three years. New Risk • Apr 05
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 31% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.9% average weekly change). Large one-off items impacting financial results. Anuncio • Mar 28
Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025 Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 New Risk • Mar 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.1% average weekly change). Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥28.83, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 21x in the Chemicals industry in China. Total returns to shareholders of 3.1% over the past three years. Reported Earnings • Mar 03
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: CN¥0.73 (up from CN¥0.54 in FY 2023). Revenue: CN¥555.0m (up 25% from FY 2023). Net income: CN¥123.6m (up 35% from FY 2023). Profit margin: 22% (up from 21% in FY 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.2%. Earnings per share (EPS) also surpassed analyst estimates by 4.3%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Anuncio • Jan 25
Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces an Equity Buyback for CNY 30 million worth of its shares. Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces a share repurchase program. Under the program, the company will repurchase up to CNY 30 million worth of its shares. The shares will be repurchased at no more than CNY 25 per share. The purpose of the program is to use the repurchased shares for equity incentive plan. If the company fails to complete the transfer within three years after the announcement of the results of the share repurchase and the share changes, the repurchased shares that have not been transferred will be cancelled. The program will be funded from company's own funds. The program will be valid for 12 months. Anuncio • Dec 27
Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025 Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025 New Risk • Nov 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Nov 12
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥25.10, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 20x in the Chemicals industry in China. Total loss to shareholders of 25% over the past three years. Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.098 (vs CN¥0.15 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.098 (down from CN¥0.15 in 3Q 2023). Revenue: CN¥126.3m (flat on 3Q 2023). Net income: CN¥16.0m (down 37% from 3Q 2023). Profit margin: 13% (down from 20% in 3Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to CN¥17.91, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 41% over the past three years. Anuncio • Sep 30
Cabio Biotech (Wuhan) Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024 Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥17.55, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 51% over the past three years. New Risk • Sep 15
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 43% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Reported Earnings • Aug 28
Second quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.13 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.26 (up from CN¥0.13 in 2Q 2023). Revenue: CN¥143.8m (up 30% from 2Q 2023). Net income: CN¥43.6m (up 112% from 2Q 2023). Profit margin: 30% (up from 19% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings. Anuncio • Aug 28
Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces an Equity Buyback for CNY 30 million worth of its shares. Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces a share repurchase program. Under the program, the company will repurchase up to CNY 30 million worth of its shares. The shares will be repurchased at no more than CNY 20 per share. The purpose of the program is to use the repurchased shares for equity incentive plan. If the company fails to complete the transfer within three years after the announcement of the results of the share repurchase and the share changes, the repurchased shares that have not been transferred will be cancelled. The program will be funded from company's own funds. The program will be valid for 12 months. New Risk • Jul 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (23% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows. Valuation Update With 7 Day Price Move • Jul 16
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥15.06, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 52% over the past three years. Anuncio • Jun 28
Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024 Anuncio • May 18
Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 06, 2024 Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 06, 2024, at 14:00 China Standard Time. Location: Meeting Room of the Company's Gedian Branch, Ezhou, Hubei China Valuation Update With 7 Day Price Move • May 03
Investor sentiment improves as stock rises 34% After last week's 34% share price gain to CN¥19.65, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 17x in the Chemicals industry in China. Total loss to shareholders of 30% over the past three years. Reported Earnings • Apr 28
First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.086 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.086 in 1Q 2023). Revenue: CN¥117.0m (up 33% from 1Q 2023). Net income: CN¥24.3m (up 70% from 1Q 2023). Profit margin: 21% (up from 16% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 26% per year whereas the company’s share price has fallen by 22% per year. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥12.36, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 56% over the past three years. Anuncio • Mar 30
Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024 Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024 Reported Earnings • Feb 26
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.54 (up from CN¥0.39 in FY 2022). Revenue: CN¥445.5m (up 2.8% from FY 2022). Net income: CN¥91.5m (up 42% from FY 2022). Profit margin: 21% (up from 15% in FY 2022). The increase in margin was primarily driven by lower expenses. Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. New Risk • Feb 25
New major risk - Revenue and earnings growth Earnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (9.7% net profit margin). Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥12.05, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 13x in the Chemicals industry in China. Total loss to shareholders of 57% over the past three years. Anuncio • Dec 29
Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024 Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024 Price Target Changed • Oct 03
Price target decreased by 16% to CN¥30.00 Down from CN¥35.71, the current price target is provided by 1 analyst. New target price is 53% above last closing price of CN¥19.57. Stock is down 30% over the past year. The company is forecast to post earnings per share of CN¥0.63 for next year compared to CN¥0.39 last year. Reported Earnings • Aug 26
Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.17 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.13 (down from CN¥0.17 in 2Q 2022). Revenue: CN¥111.0m (up 16% from 2Q 2022). Net income: CN¥20.5m (down 23% from 2Q 2022). Profit margin: 19% (down from 28% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Anuncio • May 10
Cabio Biotech (Wuhan) Co., Ltd. Showcases the New Products and Ready-To-Market Solutions At Vitafoods Europe 2023 CABIO Biotech (Wuhan) Co., Ltd. announced on May 9 to 11, 2023, the company participates in the three-day Vitafoods Europe held in Geneva, Switzerland. The company showcases three new ingredients — HMOs, Salecan® ß-glucan and elastin — as well as its already well-known ARA, algal oil DHA, ß-Carotene and sialic acid (SA) during the exhibition. HMOs, human milk oligosaccharides in full, are the significant components of breast milk and play an essential part in promoting infant brain development, maintaining intestinal microecological balance, building resistance to bacteria and viruses, and improving immunoregulation. Adult ingestion of HMOs also enhances the quality of life by contributing positively to intestinal microbiota while likely improving severe symptoms of irritable bowel syndrome (IBS). Salecan® ß-glucan is a novel water-soluble ß-glucan generated from a patented strain using the fermentation process. Approved by both FDA-GRAS and Chinese FDA New Food Ingredient Accreditation, Salecan® ß-glucan is applied extensively in food & drinks, foods for special dietary uses (FSDUs) and dietary supplements to enhance immunity, regulate intestinal microbiota, repair intestinal mucosae and improve blood lipid and sugar levels. Elastin is the main component of the elastic fiber in the skin. It works together with collagen and hyaluronic acid (HA) to maintain skin elasticity. Elastin extracted from the horse nuchal ligament contains large quantities of desmosine and isodesmosine that can smooth wrinkles, hydrate, whiten and repair the skin, plump the breasts, and lift the hips; therefore it's widely applied in food, drinks, cosmetics and skincare. As the global expert in high-end nutrient and innovative solutions, CABIO has always dedicated itself to human nutrition and health. Remaining steadfast in basic research, CABIO makes every effort to explore synthetic biology and biomedicine by mining the limitless potential consistently to offer quality ingredients and ready-to-market solutions to customers worldwide. Valuation Update With 7 Day Price Move • May 04
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥31.78, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 15% over the past three years. Reported Earnings • Apr 14
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: EPS: CN¥0.90 (down from CN¥1.07 in FY 2021). Revenue: CN¥433.4m (up 23% from FY 2021). Net income: CN¥108.7m (down 16% from FY 2021). Profit margin: 25% (down from 37% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 48%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Mar 20
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥41.68, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 15x in the Chemicals industry in China. Total returns to shareholders of 31% over the past three years. Price Target Changed • Mar 04
Price target increased by 11% to CN¥56.50 Up from CN¥51.00, the current price target is an average from 2 analysts. New target price is 15% above last closing price of CN¥49.00. Stock is up 17% over the past year. The company is forecast to post earnings per share of CN¥1.12 for next year compared to CN¥0.90 last year. Reported Earnings • Mar 02
Full year 2022 earnings released: EPS: CN¥0.90 (vs CN¥1.07 in FY 2021) Full year 2022 results: EPS: CN¥0.90 (down from CN¥1.07 in FY 2021). Revenue: CN¥433.4m (up 23% from FY 2021). Net income: CN¥108.7m (down 16% from FY 2021). Profit margin: 25% (down from 37% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥47.86, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 7.2% over the past year. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥42.44, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 14x in the Chemicals industry in China. Total loss to shareholders of 13% over the past year. Reported Earnings • Oct 25
Third quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.28 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.23 (down from CN¥0.28 in 3Q 2021). Revenue: CN¥102.1m (up 18% from 3Q 2021). Net income: CN¥27.8m (down 17% from 3Q 2021). Profit margin: 27% (down from 39% in 3Q 2021). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Valuation Update With 7 Day Price Move • Sep 21
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥37.38, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 29% over the past year. Reported Earnings • Aug 17
Second quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.28 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.23 (down from CN¥0.28 in 2Q 2021). Revenue: CN¥95.6m (up 13% from 2Q 2021). Net income: CN¥26.8m (down 21% from 2Q 2021). Profit margin: 28% (down from 40% in 2Q 2021). Over the next year, revenue is forecast to grow 47%, compared to a 42% growth forecast for the Chemicals industry in China. Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥37.67, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 17x in the Chemicals industry in China. Total loss to shareholders of 19% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥19.22 per share. Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥35.94, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 17x in the Chemicals industry in China. Total loss to shareholders of 19% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥19.74 per share. Valuation Update With 7 Day Price Move • May 11
Investor sentiment improved over the past week After last week's 24% share price gain to CN¥34.14, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 15% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥19.68 per share. Reported Earnings • Apr 27
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥1.07 (down from CN¥1.09 in FY 2020). Revenue: CN¥351.1m (up 8.5% from FY 2020). Net income: CN¥128.6m (down 1.5% from FY 2020). Profit margin: 37% (down from 40% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 13%. Over the next year, revenue is forecast to grow 47%, compared to a 43% growth forecast for the industry in China. Reported Earnings • Mar 04
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥1.07 (down from CN¥1.09 in FY 2020). Revenue: CN¥351.1m (up 8.5% from FY 2020). Net income: CN¥128.4m (down 1.6% from FY 2020). Profit margin: 37% (down from 40% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 13%. Over the next year, revenue is forecast to grow 47%, compared to a 48% growth forecast for the industry in China. Valuation Update With 7 Day Price Move • Jan 25
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥55.29, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 19x in the Chemicals industry in China. Total returns to shareholders of 24% over the past year. Valuation Update With 7 Day Price Move • Nov 25
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥57.83, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 21x in the Chemicals industry in China. Total returns to shareholders of 26% over the past year. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.32 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥86.8m (up 1.8% from 3Q 2020). Net income: CN¥33.4m (down 14% from 3Q 2020). Profit margin: 39% (down from 46% in 3Q 2020). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Sep 10
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥62.51, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 22x in the Chemicals industry in China. Total returns to shareholders of 4.6% over the past year. Reported Earnings • Aug 24
Second quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.38 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥84.3m (down 12% from 2Q 2020). Net income: CN¥33.8m (down 26% from 2Q 2020). Profit margin: 40% (down from 48% in 2Q 2020). The decrease in margin was primarily driven by lower revenue. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥52.80, the stock trades at a trailing P/E ratio of 45.5x. Average trailing P/E is 30x in the Chemicals industry in China. Total returns to shareholders of 4.7% over the past year. Valuation Update With 7 Day Price Move • Jul 02
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥50.22, the stock trades at a trailing P/E ratio of 43.3x. Average trailing P/E is 29x in the Chemicals industry in China. Total returns to shareholders of 2.8% over the past year. Valuation Update With 7 Day Price Move • May 27
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥46.35, the stock trades at a trailing P/E ratio of 39.9x. Average trailing P/E is 29x in the Chemicals industry in China. Total returns to shareholders of 14% over the past year. Reported Earnings • May 05
First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.21 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥78.8m (up 42% from 1Q 2020). Net income: CN¥33.8m (up 33% from 1Q 2020). Profit margin: 43% (down from 46% in 1Q 2020). Reported Earnings • Mar 30
Full year 2020 earnings released: EPS CN¥1.09 (vs CN¥1.31 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥323.5m (up 3.8% from FY 2019). Net income: CN¥130.6m (up 11% from FY 2019). Profit margin: 40% (up from 38% in FY 2019). Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥42.80, the stock trades at a trailing P/E ratio of 39.3x. Average trailing P/E is 36x in the Chemicals industry in China. Total returns to shareholders of 32% over the past year. Anuncio • Mar 09
CABIO Biotech(Wuhan) Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021 CABIO Biotech(Wuhan) Co., Ltd. announced that they will report fiscal year 2020 results on Mar 30, 2021 Anuncio • Jan 29
CABIO Biotech(Wuhan) Co., Ltd. (SHSE:688089) entered into an agreement to acquire 11% stake in Zhongke Optics Valley Green Biotechnology Co., Ltd. from Hefei Kejv Hi-tech Co., Ltd. for CNY 10.7 million. CABIO Biotech(Wuhan) Co., Ltd. (SHSE:688089) entered into an agreement to acquire 11% stake in Zhongke Optics Valley Green Biotechnology Co., Ltd. from Hefei Kejv Hi-tech Co., Ltd. for CNY 10.7 million on January 28, 2021. The consideration will be paid in cash and will be paid with 5 working days from effective date of this agreement. The consideration will be funded with CABIO Biotech’s own funds. Zhongke Optics Valley Green Biotechnology reported total assets of CNY 25.5 million and net assets of CNY 13.8 million as on September 30, 2020. Is New 90 Day High Low • Jan 13
New 90-day low: CN¥34.84 The company is down 39% from its price of CN¥57.20 on 15 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥38.96, the stock is trading at a trailing P/E ratio of 33.2x, down from the previous P/E ratio of 39.8x. This compares to an average P/E of 35x in the Chemicals industry in China. Total returns to shareholders over the past year are 6.2%. Is New 90 Day High Low • Dec 28
New 90-day low: CN¥38.96 The company is down 32% from its price of CN¥57.38 on 29 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 14% over the same period. Is New 90 Day High Low • Dec 11
New 90-day low: CN¥44.46 The company is down 26% from its price of CN¥60.17 on 11 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 9.0% over the same period. Is New 90 Day High Low • Nov 18
New 90-day low: CN¥46.67 The company is down 18% from its price of CN¥57.06 on 20 August 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period. Anuncio • Jul 09
CABIO Biotech(Wuhan) Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020 CABIO Biotech(Wuhan) Co., Ltd. announced that they will report first half, 2020 results on Aug 26, 2020